Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
4
×
clinical trials
investing
4
×
life sciences
national blog main
san francisco blog main
boston top stories
deals
national top stories
roche
san francisco top stories
akouos
amgen
boston
cancer
fda
venture capital
abeona therapeutics
accent therapeutics
achilles therapeutics
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceuticals
alopecia areata
amarin
aridis pharmaceuticals
aristea therapeutics
astellas pharmaceuticals
autoimmune diseases
avapritinib
axitinib
bellus health
biotech ipos
blueprint medicines
bolt biotherapeutics
boulder/denver blog main
boulder/denver top stories
bridgebio
bristol-myers squibb
What
drug
4
×
medicines
cancer
fda
ipo
advantages
affects
americans
approval
approved
bar
bio
blueprint
brings
candidate
currently
date
despite
developing
expect
family
frequency
gamble
hardest
hearing
hit
hottest
hunters
loss
market
marketing
medco’s
meds
millions
mover
muscle
new
pact
patients
payers
Language
unset
4
×
Current search:
drug
×
biotech
×
unset
×
" boston blog main "
×
investing
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
